Clinical trials: Transcatheter Arterial Chemoembolization
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) with spontaneous rupture is a potentially fatal complication and usually has poor prognosis. In most conditions, the tumors could not be radically moved.
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib
- Trial name
- NCT06740370
- Testing
- TACE, Lenvatinib, PD-1 Inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Surgery
TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC.
- Conditions
- Hepatocellular Carcinoma, Surgery, Ablation
- Trial name
- TACE-RFA (NCT01833286)
- Testing
- TACE+RFA, re-resection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma
Pain is the main complication after TACE(Transcatheter Arterial Chemoembolization) for hepatocellular carcinoma, and its pathogenesis is not clear.The pain may be related to partial liver tissue swelling after blocking the tumor…
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Pain
- Trial name
- NCT05670561
- Testing
- Esketamine, Sufentanil
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Carcinoma, Hepatocellular
Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas
Micronecrosis is a novel pathological feature of hepatocellular carcinoma (HCC). This study was aimed at evaluating the effect of tumor micronecrosis on postoperative transcatheter arterial chemoembolization (TACE) in patients…
- Trial name
- NCT05352204
- Testing
- transcatheter arterial chemoembolization
- Where
- 2 sites in China
- Volunteers
- 900 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).
- Trial name
- TACE (NCT00539253)
- Testing
- gadobenate dimeglumine (MultiHance)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced…
- Conditions
- Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
- Trial name
- NCT05984511
- Testing
- I-125 Seeds Brachytherapy in PVTT, Transcatheter arterial chemoembolization, Atezolizumab plus Bevacizumab
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Carcinoma, Hepatocellular
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.
- Trial name
- NCT00494299
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 75 sites in Japan, South Korea
- Volunteers
- 458 people
- Sponsor
- Bayer
Advanced Hepatocellular Carcinoma
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
Compared to systemic therapy alone, conversion therapy is promising to improve the prognosis of patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05738616
- Testing
- Lenvatinib combined with TACE and Camrelizumab
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Wen Tianfu
Hepatocellular Carcinoma With PVTT
Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis
The treatment for Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombosis (PVTT) is still controversial, and there is no universally agreed protocol for its treatment.
- Trial name
- NCT01350206
- Testing
- hepatic resection, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE
The purpose of this randomized, double-blind trial was to compare the effects of preemptive Oxycodone and sufentanil at the same dose on pain and inflammatory response after transcatheter arterial chemoembolization (TACE) of…
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Pain, Inflammation
- Trial name
- NCT06041425
- Testing
- Oxycodone, Sufentanil
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocellular Carcinoma
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.
- Trial name
- NCT05842317
- Testing
- Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital